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Abstract  
BACKGROUND: While dosing theophylline in asthmatics, we should consider that a lot of 
medicines, substances, conditions and diseases affect the clearance of theophylline, such as 
smoking, macrolide antibiotics, barbiturates, oral contraceptives, heart and liver insufficiency, 
alcohol, calcium-antagonists, pneumonia, viral infections, hypoxemia, etc.  
AIM: The aim of the study is to investigate the concentrations of theophylline during the day in 
smoking and nonsmoking patients with asthma.  
MATERIAL AND METHODS: We have estimated the concentrations of theophylline 6 times daily 
by the HPLC method (Keith Muir, J Chromatography) in 20 smoking and 20 nonsmoking asthmatic 
patients, who were treated with theophylline sustained-release tablets 175 mg twice daily.  
RESULTS: In the first group of 20 nonsmoking patients we obtained constant therapeutic and 
optimal concentrations of theophylline. In the second group of 20 smoking asthmatics the 
concentration of theophylline in plasma, in 8pm and 8am the next day was very low.  
CONCLUSION: Because in smokers we have increased clearance and the decreased half- life of 
theophylline, and in order to prevent the night time life-threatening attacks, it is necessary to 
recommend maximal doses of theophylline, especially in the evening. According to the study, 
dosage should be individualized in order to optimize the treatment based on the measurement of 
theophylline concentration in plasma. 
 
 
 
 
 
 
 
Introduction 
 
Asthma is a heterogeneous disease, usually 
characterized by chronic airway inflammation. It is 
defined by the history of respiratory symptoms such 
as wheeze, shortness of breath, chest tightness and 
cough that vary over time and in intensity, together 
with variable expiratory airflow limitation. Symptoms 
and airflow limitation may resolve spontaneously or in 
response to medication. Pharmacological therapy is 
an integral part and perhaps the most important part 
of all the measures included to control the asthma. 
The drugs that are used are divided into two groups. 
Anti-inflammatory or preventive medications 
“Controllers” are used to reduce the inflammation of 
the airways. Relieving or symptomatic medications 
“Relievers” are used to prevent the asthma attacks 
and the acute symptoms [1].  
Methylxanthines (Theophylline) are Relievers 
medications, which are used in the treatment of 
asthma like bronchodilators [1].
 
Theophylline was first 
extracted from tea and synthesized chemically in 1895 
and initially used as a diuretic. Its bronchodilator 
property was later identified, and it was introduced as 
a clinical treatment for asthma in 1922 [2]. 
Theophylline has become a third-line 
treatment as an add-on therapy in patients with poorly 
controlled asthma in step 2, 3 and 4, according to the 
actual version of the GINA guidelines (Global Initiative 
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of Asthma), because inhaled beta 2 agonists are far 
more effective as bronchodilators, and inhaled 
corticosteroids have a greater anti-inflammatory effect 
[1]. Theophylline is used as an oral (rapid or slow-
release tablets) for chronic treatment and 
intravenously for acute exacerbation of asthma [2, 3].  
Theophylline is a weak nonselective inhibitor 
of phosphodiesterase (PDE) isoenzymes, which break 
down cyclic nucleotides in the cell, leading to 
increased intracellular concentrations of cAMP and 
cyclic guanosine monophosphate concentrations. Its 
main effect is to relax airway smooth muscle [2].
 
The Theophylline has demonstrated efficacy 
in attenuating the three cardinal features of asthma – 
reversible airflow obstruction, airway 
hyperresponsiveness, and airway inflammation [3]. 
The combination of inhaled corticosteroids and 
theophylline exerts a synergistic anti-inflammatory 
effect that improves asthma control and reduces 
asthma exacerbations [2, 4, 6]. 
There is a close relationship between the 
acute improvement in airway function and serum 
theophylline concentrations. Below 10 mg/L 
bronchodilator effects are small, and above 25 mg/L 
additional benefits are outweighed by side effects, so 
that the therapeutic range was usually taken as 10 to 
20 mg/L, and is preferable to redefine the therapeutic 
range as 5 to 15 mg/L, which will avoid the risk of 
side-effects like anorexia, nausea, headache and 
sleep disturbance. Altered mood and behavior are 
sufficiently common to limit theophylline use in young 
children. Theophylline may also aggravate underlying 
gastro-oesophageal reflux. The dose of theophylline 
required to achieve therapeutic concentrations varies 
among patients, largely because of differences in 
clearance. Theophylline is rapidly and completely 
absorbed, but there are large interindividual variations 
in clearance, due to differences in its hepatic 
metabolism. Theophylline is metabolized in the liver 
by the cytochrome P450 microsomal enzyme system, 
and a large number of factors may influence hepatic 
metabolism. Theophylline is predominantly 
metabolized by CYP1A2. Increased clearance is seen 
in children (1–16 yr) and in cigarette and marijuana 
smokers. Concurrent administration of phenytoin, 
phenobarbitone, or rifampicin, which increases P450 
activity, increases metabolic breakdown, so that 
higher doses may be required. Reduced clearance is 
found in liver disease, pneumonia, and heart failure, 
and doses need to be reduced to one-half and plasma 
levels monitored carefully [2].
 
Decreased clearance is 
also seen with several drugs, including erythromycin, 
quinolone antibiotics (ciprofloxacin, but not ofloxacin), 
allopurinol, cimetidine (but not ranitidine), serotonin 
uptake inhibitors (fluvoxamine), and the 5-
lipoxygenase inhibitor zileuton, all of which interfere 
with CYP1A2 function. Thus, if a patient on 
maintenance theophylline requires a course of 
erythromycin, the dose of theophylline should be 
halved. Although there is a similar interaction with 
clarithromycin, there is no interaction with 
azithromycin. Viral infections and vaccinations 
(influenza immunizations) may also reduce clearance, 
and this may be particularly important in children. 
Because of these variations in clearance, 
individualization of theophylline dosage is required, 
and plasma concentrations should be measured 4 h 
after the last dose with slow release preparations, 
when steady state has usually been achieved [2]. 
Cigarette smoking remains highly prevalent in 
some countries. It can affect drug therapy by both 
pharmacokinetic and pharmacodynamic mechanisms. 
The mechanism involved in most interactions between 
cigarette smoking and drugs involves the induction of 
metabolism. Drugs for which induced metabolism 
because of cigarette smoking may have clinical 
consequence include theophylline [7]. 
In the determination of the dosing strategy of 
theophylline in asthmatic patients, it is important to 
consider the fact that a big number of medications, 
substances, conditions and diseases influence the 
clearance of the drug. This fact has serious 
therapeutic implications. For example, the smoking 
cause increase of theophylline clearance by 58–100% 
and decrease its half life (T/2) by 63% in the smokers 
organism compared with nonsmokers. This is 
because it is highly metabolized by CYP1A2. Smoking 
cessation for 1 week reduces the elimination of 
theophylline by 35% [8]. This implies a necessity of 
careful planning of the dosage and of frequent 
sampling of theophylline in plasma. 
The aim of our study is to investigate the 
concentration of theophylline during the day using the 
comparative analysis in smoking and nonsmoking 
patients with asthma. The aim of study is to show that 
dosage of theophylline should be individualized in 
order to optimize the treatment of patient with asthma. 
 
 
Material and Methods  
 
In our investigation were included 40 patients 
with diagnosed asthma. They were divided in two 
groups as follows: 1) First group were 20 nonsmoking 
asthmatics; 2) Second group were 20 patients with 
asthma who were smokers. All patients were treated 
with combined therapy with inhaled corticosteroids 
and long acting beta 2 agonist (ICS/LABA) and 
theophylline sustained-release tablets 175 mg twice 
daily. We have investigated the plasma level of 
theophylline by HPLC method, Keith Muir, J 
Chromatography [9]. The samples of blood were 
taken in 8 am and 10 am; in 2 pm, 8 pm, and 12 pm 
and then in 8 am the next morning. We used samples 
of 5 ml heparinized blood from the cubital vein, from 
which we extracted 2 ml of plasma by centrifugation. 
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Results 
 
Our results have shown that in the first group 
of nonsmoking asthmatics we achieved therapeutic 
optimal and constant concentrations of the medication 
theophylline (Fig. 1). 
 
Figure 1: Levels of theophylline obtained five times daily in 
nonsmoking asthmatic 
 
In our investigation we have found that in the 
second group of asthmatics who were smokers the 
theophyllinemia in 8 pm and 8 am on the second 
morning was extremely low (Fig. 2). 
 
Figure 2: Levels of theophylline obtained five times daily in smoking 
asthmatics 
 
In the group of 20 smoking asthmatics the 
concentration of theophylline in blood, in 8 pm and 
8am the next day was very low. These results suggest 
the need to provide and to prescribe theophylline 
therapy early in the morning and early in the evening. 
 
 
Discussion 
 
The impact of cigarette smoking needs to be 
considered in planning and assessing responses to 
drug therapy [7]. Also because of its narrow 
therapeutic range, dosage must be individualized in 
order to optimize the treatment based on the 
measurement of theophylline concentration in serum 
[3]. In our study nonsmoking asthmatics have 
therapeutic optimal and constant concentrations of the 
medication theophylline, but in the second group of 
asthmatics who were smokers, the theophyllinemia in 
8 pm and 8 am on the second morning of our study, 
was extremely low. In literature it is known that 
smoking increase theophylline metabolism [8, 10].
 
Thomson N.C and al. in their study explain that 
cigarette smoking increase the clearance of drugs by 
induction of several metabolizing enzymes. 
Cytochrome P450 1A2 is responsible for the 
metabolism of theophylline and clearance is increased 
by 60-100%in smokers compared with nonsmokers 
[8]. According to this explanation in our study we also 
noticed that the smoking cause increase of 
theophylline clearance. Because of this finding we 
suggest more frequently control of blood 
concentrations of theophylline. Barnes J.P. in his 
study about theophylline says that efficacy is related 
to blood concentration, which are determined mainly 
by hepatic metabolism, which may be increased or 
decreased [2]. Low dose of theophylline may achieve 
control of asthma comparable to a low dose of inhaled 
corticosteroids [6]. In asthmatics patients low dose 
theophylline reduce eosinophils and other 
inflammatory markers, inhibits the eosinophilia 
induced by an inhaled allergen and reduce the 
expression of cytokines such as interleukin-5 [6].
 
But, 
in smoking asthmatics in addition to eosinophilic 
airway inflammation, smoking induced neutrophilic 
airway inflammation [11, 12]. Therefore, smokers 
taking a medication that interacts with smoking may 
require higher dosages then nonsmokers [13].
 
In 
literature it is known that smokers with asthma have a 
reduced response to inhaled corticosteroid therapy 
[10, 14-17]. Alternative or additional therapies to 
inhaled corticosteroids are needed for individuals with 
asthma who are unable to quit smoking [14].
 
So, 
theophylline could be providing as additional 
medication to inhaled corticosteroids in smoking 
asthmatics. 
In conclusion, in our study in nonsmoking 
asthmatics we achieved therapeutic optimal and 
constant theophylline concentrations, which lead to 
subsequent therapeutic effects. In the smoking 
asthmatics in 8 pm and 8 am on the second morning 
of the examination, the concentrations of theophylline 
were extremely low. We suggest that this low 
concentration is result of the increased clearance and 
the decreased T/2 of theophylline in smokers. 
Because of the increased clearance and the 
decreased half-life of theophylline in smokers, and in 
order to prevent the night time life-threatening attacks, 
it is necessary to recommend maximal doses of 
theophylline, especially in the evening. Having in mind 
these facts, it is important for smoking asthmatics, to 
provide and to prescribe theophylline therapy early in 
the morning and early in the evening and to control 
the plasma concentrations of theophylline more 
frequently.  
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